Status:
NOT_YET_RECRUITING
Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE)
Lead Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
Stroke
Ischemic Stroke
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
IMMUNOSTROKE study aims to describe the immuno-inflammatory and thrombo-inflammatory profiles during the course of AIC management by reperfusion treatment and to monitor changes in these different par...
Eligibility Criteria
Inclusion
- Presenting an ISCHEMIC STROKE for which reperfusion treatment is indicated according to European and North American recommendations (intraveinous thrombolysis or mechanical thrombectomy or a combination of both)
Exclusion
- Contraindication to performing a cerebral MRI (claustrophobia, pacemaker or other implantable device contraindicating the performance of MRI)
- Intracranial haemorrhage associated with AIC on initial imaging
- Immunosuppressive treatment or corticosteroid therapy on admission of the patient
- Pre-existing neurological disability limiting the neurological assessment to 3 months (mRS\>2 on admission)
- Dementia known and diagnosed pre-existing at ischemic stroke
- Absolute or relative contraindication to gadolinium injection (history of true allergic reaction or intolerance to gadobutrol, renal failure with creatinine clearance \<15mL/min, pregnant or breastfeeding woman).
Key Trial Info
Start Date :
September 15 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 15 2028
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04701619
Start Date
September 15 2026
End Date
May 15 2028
Last Update
June 25 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.